2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4173 Inb-100: Phase 1 and expansion cohort study of allogeneic engineered gamma-delta T cell infusion following haploidentical hematopoietic stem-cell transplantation in leukemia patients

Joseph P McGuirk, DO, Sarah Wall, MD,MPH2, Stacey Bilinski3, Kate Rochlin, PhD4, Lawrence Lamb Jr, MN, PhD5
1 University of Kansas Cancer Center, Kansas City, Kansas, United States
2 Ohio State University Medical Center, Columbus, Ohio, United States
3 IN8Bio, Inc, New York, New York, United States
4 IN8Bio, Inc, New York, New York, United States
5 IN8Bio, Inc, New York, New York, United States

Background: Disease recurrence in Leukemia patients following stem cell transplant (SCT) with cyclophosphamide prophylaxis (Haplo/Cy) remains a significant problem, often leading to death. Patients are particularly susceptible to relapse in the early months following SCT prior to complete immune reconstitution.  Patients who naturally recover high levels of circulating γδ T cells following BMT show a significant improvement in long-term relapse-free survival (RFS).  Gamma-delta (γδ) T cells engage and eliminate cancer cells via innate sensing of multiple ligands, such as DNAM-1 and NKG2DL, but do not initiate graft-versus-host disease (GvHD), suggesting that they could provide effective prophylaxis against recurrence early in the post-HSCT setting. In this Phase I trial, and RP2D expansion cohort, we examine whether a single infusion of allogeneic ex vivo expanded and activated γδ T cells (EAGD) can improve RFS and overall (OS) survival with manageable safety in leukemia patients following Haplo/Cy HSCT.

Methods: Adults with newly diagnosed or recurrent ALL, CML, AML, or MDS undergoing Haplo/Cy BMT/PBSC following a reduced intensity conditioning (RIC) regimen receive an infusion of ex vivo expanded and activated γδ (EAGD) cells from the haploidentical SCT donor within 7 days of neutrophil engraftment. Primary endpoints include dose-limiting toxicities (DLT), grade 3-4 adverse events, with secondary endpoints of RFS and OS.

Results: Of the 30 subjects enrolled, 23 were treated; 4 at dose level (DL)1 of 1x106 cells/kg and 6 at DL2 of 3x106 cells/kg. An expansion cohort of 13 patients were treated at DL2, the RP2D. Subjects are 56.5% male, median age 66, 65.2% AML, 21.7% MDS, 8.7% ALL and 4.3% CML.  Common treatment-emergent AEs included anemia, neutropenia, thrombocytopenia hypomagnesemia, and increased creatinine which are generally associated with BMT. The incidence of acute GvHD was 35%, comparable to that expected with RIC Haplo/Cy BMT.. No DLTs, neurotoxicity, cytokine release syndrome or treatment related deaths reported. At median follow-up of 18.4 months (m), 12.4+m median duration of morphologic CR was observed. For AML patients, median CR is 15.5+m and climbing, with 90% RFS to-date. 3 high-risk AML patients remain relapse free beyond 3 years, including 2 with trisomy 8 and del 7 with IDH and/or FLT-3 mutations.

Summary: EAGD cells demonstrate a manageable safety profile. Durable RFS ≥ 12mos was achieved in 76.5% of total and 90% of AML subjects, comparing favorably with historically expected ~51% RFS at 1-year for HaploCy SCT. The improved survival suggests that a promising association between EAGD infusion and protection against relapse after HaploCy SCT in difficult-to-treat patents.

Lawrence Lamb Jr, MN, PhD: IN8Bio, Inc. - Current equity holder in publicly-traded company; IN8Bio, Inc. - Stock (publicly traded); IN8Bio, Inc. - Research Funding; IN8Bio, Inc. - Patents & Royalties; IN8Bio, Inc. - Current Employment